Antibiotic Resistance Biology

Introduction to Antibiotic Resistance

Antibiotic resistance occurs when bacteria evolve mechanisms that reduce or eliminate the effectiveness of antibiotics, rendering standard treatments ineffective. The WHO classifies antibiotic resistance as one of the top 10 global public health threats. Antimicrobial resistance (AMR) killed approximately 1.27 million people directly in 2019 and contributed to 4.95 million deaths; without action, AMR deaths could reach 10 million per year by 2050 exceeding cancer mortality. Resistance arises through intrinsic (naturally occurring structural or biochemical features), acquired (mutations or horizontally transferred genes), and adaptive (transient regulation) mechanisms.

Alexander Fleming predicted antibiotic resistance in his 1945 Nobel Prize lecture—observing that subtherapeutic penicillin exposure could select resistant mutants. Since then, resistance has emerged to every antibiotic within years of deployment. The antibiotic discovery void—no new antibiotic classes (targeting novel mechanisms) have reached clinical use since the 1980s—combined with increasing global resistance reflects a failure of innovation and market incentives for antibiotic development. ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species) represent the most urgent resistant threat organisms requiring new treatment options.

Mechanisms of Antibiotic Resistance

Enzymatic Inactivation

Beta-lactamases hydrolyse the beta-lactam ring of penicillins and cephalosporins, inactivating them before they reach their PBP target. Extended-spectrum beta-lactamases (ESBLs—TEM, SHV, CTX-M) confer resistance to expanded-spectrum cephalosporins; metallo-beta-lactamases (NDM-1, VIM, IMP) also hydrolyse carbapenems (last-resort antibiotics), creating extensively drug-resistant (XDR) organisms. Aminoglycoside-modifying enzymes (acetyltransferases, phosphoryltransferases, nucleotidyltransferases) modify hydroxyl or amino groups blocking ribosomal binding. Chloramphenicol acetyltransferases acetylate the drug preventing its binding to 50S ribosome. These enzymatic mechanisms often reside on mobile genetic elements spreading rapidly across bacteria.

Target Modification

Modifying the antibiotic target reduces binding affinity while maintaining function for the bacterium. MRSA (methicillin-resistant Staphylococcus aureus) carries mecA encoding PBP2a—a modified penicillin-binding protein with low affinity for beta-lactams, acquired from a commensal staphylococcal species by HGT. Macrolide-resistant bacteria methylate 23S rRNA (erm genes) reducing erythromycin binding to 50S ribosome—the same site modified by some resistance genes in ribosome-producing bacteria as self-resistance. Quinolone-resistant bacteria carry gyrA and parC point mutations in the quinolone resistance-determining region (QRDR) reducing drug-target interactions while maintaining essential topoisomerase function. Point mutations in rpoB cause rifampicin resistance in Mycobacterium tuberculosis.

Horizontal Gene Transfer and Mobile Genetics

Conjugative Plasmids

Conjugative plasmids are replicons carrying their own transfer machinery (Tra genes)—forming mating junctions (pili and membrane channels) between donor and recipient bacteria enabling DNA transfer without cell fusion. Resistance genes (often as integrons carrying multiple resistance gene cassettes) are mobilised on conjugative plasmids, enabling rapid spread of multi-drug resistance across bacterial species within microbial communities. The emergence of carbapenem-resistant Enterobacteriaceae (CRE) has been driven by conjugative spread of KPC-carrying plasmids across Klebsiella pneumoniae and E. coli globally. Surveillance of plasmid epidemiology through whole-genome sequencing tracks resistance element spread and identifies transmission networks.

Integrons and Transposons

Integrons are genetic elements capturing resistance gene cassettes at their attI site and expressing them from a common Pc promoter. Class 1 integrons are the most clinically important—carrying 1-8 resistance gene cassettes providing multi-drug resistance to aminoglycosides, sulfonamides, trimethoprim, chloramphenicol, and other antibiotics simultaneously. Many class 1 integrons are embedded within transposons (Tn21, Tn402), which are themselves carried on conjugative plasmids—creating nested mobile elements enabling efficient multi-drug resistance assembly and dissemination. Advanced sequencing of class 1 integron regions in clinical and environmental samples quantifies the resistance gene pool circulating in microbiomes.

New Approaches to Combat Resistance

Antibiotic development pipeline improvements: FDA GAIN Act incentives and BARDA funding have supported development of new beta-lactam/beta-lactamase inhibitor combinations (ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-cilastatin-relebactam) specifically targeting KPC, OXA-48, and MBL carbapenemases. Completely novel mechanisms of action include teixobactin (targeting lipids II and III for cell wall synthesis, isolated from uncultured bacteria using the iChip soil culturing device), mupirocin analogues, and LolCDE inhibitors preventing lipoprotein transfer. Phage therapy, CRISPR-based antimicrobials selectively targeting resistance genes or specific bacterial strains, and anti-virulence approaches are non-antibiotic alternatives in development.

Examples and Applications

Example 1: MRSA Global Spread

Hospital-acquired MRSA emerged in the 1960s shortly after methicillin introduction; community-acquired MRSA (CA-MRSA) clones (USA300 in North America, ST59 in Asia-Pacific) spread in the 2000s causing skin/soft tissue infections in previously healthy individuals outside healthcare settings. USA300 CA-MRSA carries PVL (Panton-Valentine leukocidin) toxin causing severe necrotising skin infections and pneumonia. Genomic epidemiology traced the clonal expansion and spread of USA300 from its origin in North America. Vancomycin resistance (VRSA from VanA gene transfer from VRE to MRSA) has emerged sporadically but not spread due to fitness costs—so far. MRSA colonisation decolonisation strategies (intranasal mupirocin + chlorhexidine washes) reduce surgical site infection rates.

Example 2: Carbapenem-Resistant Klebsiella

NDM-1 (New Delhi Metallo-beta-lactamase) was first identified in a Swedish patient hospitalised in India in 2008; within 3 years it appeared in Klebsiella, E. coli, and other Enterobacteriaceae globally. NDM-1-positive bacteria are resistant to virtually all beta-lactams including carbapenems, leaving few treatment options (colistin, tigecycline, fosfomycin—each with significant toxicity and resistance risks). Genomic surveillance established that NDM-1 spread on a diverse collection of plasmids, preventing control by clone-specific measures. New options: ceftazidime-avibactam (though avibactam does not inhibit MBLs), aztreonam-avibactam combination (aztreonam is stable to MBLs; avibactam inhibits co-produced ESBLs), and cefiderocol (a siderophore cephalosporin).

Example 3: Tuberculosis Drug Resistance

Multidrug-resistant TB (MDR-TB)—resistant to isoniazid and rifampicin—affects approximately 450,000 people annually, requiring 9-20 months of second-line drugs with severe side effects. Extensively drug-resistant TB (XDR-TB) additionally resistant to fluoroquinolones and injectable agents affects approximately 40,000 per year with very limited treatment options. Whole-genome sequencing rapidly predicts drug susceptibility from resistance-associated mutations in rpoB (rifampicin), katG/inhA (isoniazid), gyrA (fluoroquinolones), rrs/eis (aminoglycosides)—enabling rapid targeted therapy without traditional 6-week DST wait. New drugs bedaquiline (ATP synthase inhibitor), pretomanid, and delamanid (nitroimidazoles) approved in 2012-2019 provide the first new TB treatment options in 40 years.

Example 4: Antibiotic Stewardship

Antibiotic stewardship programmes (ASPs) in hospitals systematically optimise antibiotic prescribing to reduce unnecessary use, empirically select appropriate agents, and shorten durations to minimum effective periods. Hospital ASPs reduce antibiotic consumption by 20-30%, decrease C. difficile infection rates, shorten hospital stays, and reduce resistance emergence. Key elements: formulary restriction, pre-authorisation of broad-spectrum agents, prospective audit and feedback, rapid diagnostic integration enabling de-escalation within 48 hours, and pharmacist-driven dose optimisation using pharmacokinetic/pharmacodynamic modelling. National One Health action plans addressing agricultural antibiotic use—animals consume 70% of all antibiotics globally—complement hospital stewardship in reducing resistance selection pressure.

Example 5: Bacteriophage Therapy

Bacteriophages—viruses infecting bacteria—were therapeutic agents before antibiotics and are experiencing a renaissance as last-resort treatment for MDR/XDR bacteria. Phage therapy requires matching patient-specific bacterial isolates with lytic phages from libraries or specifically isolated from environmental sources. Published compassionate use cases include successful eradication of MDR Acinetobacter baumannii endocarditis (UC San Diego, 2016), MDR E. coli liver abscess, and prosthetic joint infections. Phage cocktails reduce resistance emergence risk. Challenges include rapid immune clearance, strain specificity requiring large phage libraries, engineering anti-phage resistance in bacteria, and regulatory pathways for individualized phage products. Phage banks in Belgium and Poland provide therapeutic phages through international access frameworks.

Example 6: Rapid Diagnostics and Antibiotic Prescribing

Rapid diagnostic tests enable targeted antibiotic therapy rather than empirical broad-spectrum treatment. MALDI-TOF mass spectrometry identifies bacterial species from positive blood cultures in minutes versus hours; rapid PCR panels (BioFire FilmArray) simultaneously detect 24 pathogens and resistance genes from blood, CSF, and respiratory samples within 1 hour. Rapid susceptibility phenotype testing (Alfred AST, Accelerate Pheno) provides MICs within 7 hours from positive blood culture versus 48-72 hours for conventional methods, enabling earlier de-escalation from broad-spectrum empirical antibiotics. Whole-genome sequencing turnaround of 12-24 hours for direct clinical specimens is being validated for clinical decision-support in TB and MRSA management.

Example 7: Colistin Resistance and Last-Resort Antibiotics

Colistin (polymyxin E), a last-resort antibiotic against CRE, was considered resistance-free because chromosomal mutations causing resistance impose high fitness costs. In 2015, Liu et al. reported plasmid-mediated colistin resistance through the mcr-1 gene (MCR-1 enzyme adding phosphoethanolamine to lipid A reducing colistin binding) in Chinese clinical and agricultural Enterobacteriaceae. MCR-1 spread globally on conjugative plasmids within months of discovery—the same agricultural ecosystem where colistin was used as a growth promoter. China banned colistin as an agricultural growth promoter in 2016; within one year MCR-1 prevalence in food animals and patients significantly declined, demonstrating that removing agricultural antibiotic use can reverse resistance gene prevalence within months.

Example 8: Synthetic Approaches to Novel Antibiotics

Teixobactin was isolated from Eleftheria terrae—a previously uncultured soil bacterium—using iChip technology enabling in situ cultivation by maintaining bacteria in their native soil environment in permeable containers implanted back in soil while growing normally. Teixobactin binds the lipid II (peptidoglycan precursor) and lipid III (wall teichoic acid precursor) flipping portions of cell wall synthesis, killing Gram-positive bacteria including MRSA, VRE, and drug-resistant M. tuberculosis at nanomolar concentrations. No resistance to teixobactin was detected in laboratory experiments over many passages—possibly because its lipid II target cannot tolerate mutations (resistance would require altering fundamental cell wall synthesis tolerating fatal structural change). Clinical development is ongoing targeting MRSA infections.

Try it live

Everything above runs in your browser — open Antibiotic Resistance: Bacterial Evolution Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.